BRAWN BIOTECH LTD. is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 9 | 22 | 16 | 13 | 17 |
| EBITDA (ex other income) | (2) | (0) | (2) | (2) | (0) |
| margin % | (23.3) | (1.4) | (9.3) | (13.2) | (1.9) |
| Owners' profit | (2) | (1) | (2) | (2) | 1 |
| EPS, as reported (₹) | (5.25) | (3.04) | (5.14) | 5.87 | 3.26 |
| ROE % · ROCE % | (22.8) · (27.5) | (13.8) · (6.2) | (30.5) · (19.1) | (53.5) · (16.1) | 21.7 · 0.1 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 0 | 0 | (0) | 0 | 0 |
| Capex | (0) | (0) | (0) | (0) | (0) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 4 | 2 | 6 | 5 | 4 | 2 | 6 |
| Profit before tax | (0) | (0) | (0) | 0 | 0 | 0 | (0) | 0 |
| Net profit | (0) | (0) | (0) | 0 | 0 | 0 | 1 | 0 |
| EPS (₹) | (0.96) | (1.44) | 1.65 | 0.89 | 0.25 | 0.17 | 1.95 | 0.52 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 2 Sept 2026 · Letters to shareholders for AGM notice and annual report FY2025-26 | compliance | minimal | — | — |
| 2 Sept 2026 · Newspaper publication of 41st AGM notice filed with BSE | compliance | minimal | — | — |
| 1 Sept 2026 · Brawn Biotech FY26 annual report: revenue up 26%, loss narrows | results | high | — | — |
| 1 Sept 2026 · Brawn Biotech 41st AGM on Sep 29 2026; new auditor and manager pay approval on agenda | board shareholder meetings | low | — | — |
| 14 Aug 2026 · Brawn Biotech Q1 FY26 Results: Revenue Up, Profit Down | compliance | minimal | — | — |
| 13 Aug 2026 · Brawn Biotech Q1 FY27 results, new auditor recommended for 5-year term | results | high | — | — |
| 13 Aug 2026 · Q1 FY27 results approved; new statutory auditor recommended | results | medium | — | — |
| 5 Aug 2026 · Board meeting on Aug 13, 2026 to consider Q1 FY27 results | results | low | — | — |
| 8 Jul 2026 · Routine quarterly compliance certificate under SEBI Reg 74(5) | compliance | minimal | — | — |
| 25 Jun 2026 · Trading window closed for quarter ended June 30 2026 | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 7.7 | 28.9 | 18 of 169 | 90% |
| P/B | 1.5 | 3.3 | 35 of 163 | 78% |
| ROCE | 0.0 | 10.8 | 153 of 183 | 17% |
| ROE | 21.7 | 10.4 | 17 of 171 | 91% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 3.0 | 17.5 | 149 of 165 | 10% |
| Revenue growth | 4.8 | 16.3 | 114 of 161 | 29% |
| Profit growth | (34.6) | 30.9 | 123 of 158 | 22% |
| Market cap | 7 | 839 | 179 of 182 | 2% |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
